MetaCap

Aldeyra Therapeutics (ALDX) vs XBiotech (XBIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

XBiotech (XBIT) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 24.1% versus a loss of 83.1%. Over five years, XBIT leads with a -86.5% price change compared with -89.1% for ALDX. XBiotech is the larger company by market cap ($52.7 million vs $50.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALDX-83.06%XBIT-24.12%
+24%-35%-94%
Nov 21, 20251 yearNov 20, 2026
ALDX-89.41%XBIT-86.35%
+46%-27%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALDX versus XBIT key metrics
MetricALDXXBIT
Share price$0.84$1.73
Market cap$50.70M$52.74M
1-day change+16.39%+2.98%
YTD return-83.78%-27.62%
1-year return-83.06%-24.12%
5-year return-89.06%-86.48%
Forward P/E—13.31
EPS (TTM)$-0.31$-1.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-33.85M$-45.54M
52-week high$5.93$2.73
52-week low$0.527$1.61
Distance from 52-week high-85.83%-36.63%
Analyst consensusstrong_buy—
Avg. price target upside+685.71%—
Average volume1.16M64.77K
Shares outstanding60.36M30.49M
Employees687
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XBIT has outperformed ALDX by 58.9 percentage points over the past year.

About Aldeyra Therapeutics

ALDX stock →

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About XBiotech

XBIT stock →

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

ALDX vs XBIT FAQ

Which is bigger, Aldeyra Therapeutics or XBiotech?

XBiotech (XBIT) is larger, with a market capitalization of $52.74M compared with $50.70M for Aldeyra Therapeutics (ALDX).

Which stock has performed better over the past year, ALDX or XBIT?

XBIT returned -24.12% over the past 12 months, compared with -83.06% for ALDX (price return, excluding dividends). Past performance does not predict future results.

Are Aldeyra Therapeutics and XBiotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons